<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">morpho</journal-id><journal-title-group><journal-title xml:lang="ru">Морфологические ведомости</journal-title><trans-title-group xml:lang="en"><trans-title>Morphological newsletter</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1812-3171</issn><issn pub-type="epub">2686-8741</issn><publisher><publisher-name>Private Medical University REAVIZ</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20340/mv-mn.18(26).02.12-16</article-id><article-id custom-type="elpub" pub-id-type="custom">morpho-113</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>RESEARCH ARTICLES</subject></subj-group></article-categories><title-group><article-title>МОРФОЛОГИЧЕСКАЯ СТРУКТУРА ПЕЧЕНИ И ЕЕ ФУНКЦИОНАЛЬНОЕ СОСТОЯНИЕ ПРИ ЛЕКАРСТВЕННОМ ПОРАЖЕНИИ И ЛЕЧЕНИИ НОВОЙ ФАРМАЦЕВТИЧЕСКОЙ КОМПОЗИЦИЕЙ</article-title><trans-title-group xml:lang="en"><trans-title>THE MORPHOLOGICAL STRUCTURE OF THE LIVER AND ITS FUNCTIONAL STATE AT MEDICINAL DAMAGE AND TREATMENT BY THE NEW PHARMACEUTICAL COMPOSITION</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Морозов</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Morozov</surname><given-names>M. A.</given-names></name></name-alternatives><email xlink:type="simple">bev-saransk@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Блинова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Blinova</surname><given-names>E. V.</given-names></name></name-alternatives><email xlink:type="simple">bev-saransk@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Овсепян</surname><given-names>Ж. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ovsepyan</surname><given-names>G. A.</given-names></name></name-alternatives><email xlink:type="simple">bev-saransk@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дыдыкин</surname><given-names>С. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Dydykin</surname><given-names>S. S.</given-names></name></name-alternatives><email xlink:type="simple">dydykin_ss@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Блинов</surname><given-names>Д. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Blinov</surname><given-names>D. S.</given-names></name></name-alternatives><email xlink:type="simple">bev-saransk@yandex.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Горшков</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gorshkov</surname><given-names>V. A.</given-names></name></name-alternatives><email xlink:type="simple">bev-saransk@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пронина</surname><given-names>Е. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Pronina</surname><given-names>E. N.</given-names></name></name-alternatives><email xlink:type="simple">bev-saransk@yandex.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Балашов</surname><given-names>В. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Balashov</surname><given-names>V. P.</given-names></name></name-alternatives><email xlink:type="simple">bev-saransk@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Семелева</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Semeleva</surname><given-names>E. V.</given-names></name></name-alternatives><email xlink:type="simple">bev-saransk@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Степанова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Stepanova</surname><given-names>A. A.</given-names></name></name-alternatives><email xlink:type="simple">bev-saransk@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ogarev National Research Mordovian State University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Первый Московский государственный медицинский университет им. И.М. Сеченова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov First Moscow State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Всероссийский научный центр по безопасности биологически активных веществ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>All-Russian Scientific Center for the Safety of Biologically Active Substances</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Бюро судебно-медицинской экспертизы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Bureau of Forensic Medical Examination</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>30</day><month>06</month><year>2018</year></pub-date><volume>26</volume><issue>2</issue><fpage>12</fpage><lpage>16</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Морозов М.А., Блинова Е.В., Овсепян Ж.А., Дыдыкин С.С., Блинов Д.С., Горшков В.А., Пронина Е.Н., Балашов В.П., Семелева Е.В., Степанова А.А., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Морозов М.А., Блинова Е.В., Овсепян Ж.А., Дыдыкин С.С., Блинов Д.С., Горшков В.А., Пронина Е.Н., Балашов В.П., Семелева Е.В., Степанова А.А.</copyright-holder><copyright-holder xml:lang="en">Morozov M.A., Blinova E.V., Ovsepyan G.A., Dydykin S.S., Blinov D.S., Gorshkov V.A., Pronina E.N., Balashov V.P., Semeleva E.V., Stepanova A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.morpholetter.com/jour/article/view/113">https://www.morpholetter.com/jour/article/view/113</self-uri><abstract><p>В работе представлены результаты исследования функциональной активности и описания морфологической структуры печени при экспериментальном моделировании лекарственного гепатита путем двукратного введения парацетамола в дозе 1000 мг/кг белым нелинейным крысам обоего пола на фоне профилактического введения фармацевтической композиции с лабораторным шифром ЛХТ-8-16. Исследуемое вещество вводили животным внутрижелудочно за 1 час до введения гепатотоксина. Изучены изменения биохимических показателей крови, характеризующие функциональную активность печени, оценена её гистологическая картина, а также проведена макро- и микроморфометрия органа. Показано, что вещество ЛХТ-8-16 предотвращает токсическое действие парацетамола на функциональную активность печени, что проявляется в снижении активности парацетамол-индуцированного цитолитического и холестатического синдромов, нормализации уровня общего билирубина в плазме крови животных. Внешний вид печени, её относительная и абсолютная масса у животных с лекарственным гепатитом, получавших ЛХТ-8-16, была сопоставима с интактными крысами. На гистологических препаратах, окрашенных гематоксилином и эозином, наблюдалось уменьшение площади некроза печеночной паренхимы, сохранялась балочная структура ткани, гиперемия и расширение синусоидов имели место на периферии органа и носили менее выраженный характер в сравнении с группой контроля. Площадь цитоплазмы, ядра и ядерно-цитоплазматическое соотношение приближались к значениям интактной группы. Появление многоядерных гепатоцитов свидетельствовало об активизации синтетической активности печени и запуске механизмов регенерации. Таким образом, можно сделать вывод о том, что изучаемая фармацевтическая композиция обладает гепатопротекторым эффектом.</p></abstract><trans-abstract xml:lang="en"><p>The study presented results of exploration of liver functional activity and morphological structure on the experimental model of drug-induced hepatitis by twice administration of 1000 mg/kg acetaminophen to nonlinear both sexes white rats treated by preventive administration of novel pharmaceutic formulation with laboratory code LHT-8-16. The substance was administered to the animals intra-gastrically 1 hour prior to acetaminophen intake. We studied changes in biochemical blood indices, which characterize the functional activity of the liver, assessed the organ histological structure, and performed macro- and micro-morphometric analysis. It has been shown that the substance LHT-8-16 prevents the toxic effect of acetaminophen on the functional activity of the liver, which was displayed in the decrease of activity of drug-induced cytolytic and cholestatic syndromes, normalizing the level of total bilirubin in rats’ serum. The appearance of the liver, its relative and absolute weight in animals with drug-induced hepatitis, who received LHT-8-16, was comparable with the intact rats. On histological specimens stained with hematoxylin and eosin we observed a decrease in the area of necrosis of hepatic parenchyma, preservation of tissue structure. Hyperemia and extending sinusoids occurred on the periphery of the body and were less pronounced in comparison with the control group. The area of the cytoplasm, the nuclei and the nuclear-cytoplasmic ratio approximated the values of the intact group. The appearance of multi-nuclear hepatocytes referred to the activation of the synthetic activity of the liver and onset of regeneration mechanisms. Thus, it can be concluded that the studied formulation possesses hepatoprotective property.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>морфология печени</kwd><kwd>лекарственный гепатит</kwd><kwd>парацетамол</kwd><kwd>препарат ЛХТ-8-16</kwd></kwd-group><kwd-group xml:lang="en"><kwd>liver morphology</kwd><kwd>drug-induced hepatitis</kwd><kwd>paracetamol</kwd><kwd>drug LKHT-8-16</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bataller L, Hadengue A, Zoulim F. Barselona. Spain. 2012;1:35-40.</mixed-citation><mixed-citation xml:lang="en">Bataller L, Hadengue A, Zoulim F. Barselona. Spain. 2012;1:35-40.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lopatkina TN, Burnevich EZ. Lekarstvennye porageniy pecheni. Prakticheskaya gepatologiya. 2004;133-136.</mixed-citation><mixed-citation xml:lang="en">Lopatkina TN, Burnevich EZ. Lekarstvennye porageniy pecheni. Prakticheskaya gepatologiya. 2004;133-136.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Polunina TE. iDoctor.2013:5:23-28.</mixed-citation><mixed-citation xml:lang="en">Polunina TE. iDoctor.2013:5:23-28.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bjornsson E, Olsson R. Outcome and prognostic markers insevere drug induced liver disease. Hepatology. 2005;42:481-489.</mixed-citation><mixed-citation xml:lang="en">Bjornsson E, Olsson R. Outcome and prognostic markers insevere drug induced liver disease. Hepatology. 2005;42:481-489.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Koroleva MV. Exogennj-toxicheskii gepatit. Sovremennyi vzglyad na etiologiu, patogenez, klinicheskoe techenie. Lekarstvennyi vestnik. 2015;2(58)9:18-22.</mixed-citation><mixed-citation xml:lang="en">Koroleva MV. Exogennj-toxicheskii gepatit. Sovremennyi vzglyad na etiologiu, patogenez, klinicheskoe techenie. Lekarstvennyi vestnik. 2015;2(58)9:18-22.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kafrouni MI, Anders RA, Verma S. Gepatotoxichnost, obuslovlennaya primeneniem dieticheskih dobavok, sodergashih anaboliticheskie steroidy. Clinicheskaya Gastroenterologya i gepatologiya. 2009;2(3):163-167.</mixed-citation><mixed-citation xml:lang="en">Kafrouni MI, Anders RA, Verma S. Gepatotoxichnost, obuslovlennaya primeneniem dieticheskih dobavok, sodergashih anaboliticheskie steroidy. Clinicheskaya Gastroenterologya i gepatologiya. 2009;2(3):163-167.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Eremina EU. Lekarstvennyi gepatit. Practicheskaya medicina. 2014;1(77):20-29.</mixed-citation><mixed-citation xml:lang="en">Eremina EU. Lekarstvennyi gepatit. Practicheskaya medicina. 2014;1(77):20-29.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kullak-Ublick GA, Andrade RJ, Merz M et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment Gut. 2017;3:1-11.</mixed-citation><mixed-citation xml:lang="en">Kullak-Ublick GA, Andrade RJ, Merz M et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment Gut. 2017;3:1-11.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Rivera P, Pastor A, Arrabal S et al. Acetaminophen-induced liver injury alters the acyl ethanolamine-based anti-inflammatory signaling system in liver. Front Pharmacol. 2017;8:705.</mixed-citation><mixed-citation xml:lang="en">Rivera P, Pastor A, Arrabal S et al. Acetaminophen-induced liver injury alters the acyl ethanolamine-based anti-inflammatory signaling system in liver. Front Pharmacol. 2017;8:705.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ratziu V, Harrison SA, Francque S et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150:1147-1159.</mixed-citation><mixed-citation xml:lang="en">Ratziu V, Harrison SA, Francque S et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150:1147-1159.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
